Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | December 29, 2011 | December 21, 2012 |
| AbbVie Inc.ABBV · Entity 2800 | Director | March 31, 2025 | April 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 29, 2011 · Filed December 21, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 49,432 |
Reported balance
After 2011-12-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2011-12-29 · Gift · Disposed 24,982 · Balance 49,432 F1: Reflects the transfer of 111,161 Abbott common shares that was exempt from Section 16. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the transfer of 111,161 Abbott common shares that was exempt from Section 16.
AbbVie Inc.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 386,479 |
Reported balance
After 2025-03-31 transaction · row 1
1 source rowRow 1 · 2025-03-31 · Gift · Disposed 2,450 · Balance 386,479 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2018 Filed Mar 2, 2018 17:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 79,491 | $118.26 | $9,400,605.66 |
DisclosureSEC source: 0001179110-18-003329 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,292 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:57 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 127,610 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002302 · edgar.xml · derivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,610 Underlying: Common Stock · 127,610 shares Expires 2028-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 42,537 on February 15, 2019, 42,536 on February 15, 2020, and 42,537 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:57 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 39,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002302 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,783 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:57 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 45,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002302 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,672 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:57 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 42,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002302 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,486 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 16:55 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 218,193 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-17-014593 · edgar.xml · derivative · entry 6 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,097 Underlying: Common stock, $0.01 par value · 218,193 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 16:55 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 218,193 | $94.01 | $20,511,800.27 |
DisclosureSEC source: 0001179110-17-014593 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,837 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.34, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 16:55 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 218,193 | $58.88 | $12,847,203.84 |
DisclosureSEC source: 0001179110-17-014593 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 13, 2017 17:25 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 2,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-014052 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,837 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 193,131 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · derivative · entry 19 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 193,131 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,200 | $71.03 | $85,236.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 15 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,492 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 9,618 | $71.01 | $682,974.18 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 14 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,692 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 446 | $71.04 | $31,681.61 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 13 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,310 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 3,158 | $71.02 | $224,281.16 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 12 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,756 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 2,602 | $71.04 | $184,846.08 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 11 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,914 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,100 | $71.05 | $78,149.50 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 10 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,516 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 157,163 | $71.00 | $11,158,573.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,616 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,800 | $71.06 | $127,908.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,779 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,153 | $71.02 | $81,880.30 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,579 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 6,200 | $71.05 | $440,510.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 6 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,732 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 3 | $71.07 | $213.20 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,932 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 100 | $71.06 | $7,105.50 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,935 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,809 | $71.03 | $128,484.23 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,035 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 6,779 | $71.01 | $481,342.90 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,844 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 193,131 | $51.42 | $9,930,796.02 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 22,038 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · derivative · entry 16 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,131 Underlying: Common stock · 22,038 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 737 | $71.13 | $52,422.81 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 11 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,492 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 200 | $71.11 | $14,222.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 10 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,229 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 500 | $71.11 | $35,552.50 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,429 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,900 | $71.08 | $135,052.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,929 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 3,000 | $71.07 | $213,210.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,829 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 15,600 | $71.06 | $1,108,536.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 6 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,829 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 101 | $71.00 | $7,171.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,429 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 22,038 | $51.42 | $1,133,193.96 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 65,861 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · derivative · entry 15 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,169 Underlying: Common stock · 65,861 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 35 | $71.01 | $2,485.18 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,530 Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 65,826 | $71.00 | $4,673,646.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,565 Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 65,861 | $51.42 | $3,386,572.62 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2017 Filed Jun 30, 2017 17:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 2,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009834 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,492 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,100 | $65.52 | $72,066.50 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 17 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,727 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,300 | $65.51 | $85,163.00 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 16 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,827 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 700 | $65.51 | $45,855.25 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 15 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,127 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 30,549 | $65.51 | $2,001,112.25 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 14 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,827 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 200 | $65.50 | $13,100.00 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 13 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,376 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,600 | $65.50 | $104,792.00 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 12 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,576 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 800 | $65.49 | $52,392.00 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 11 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,176 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 8,175 | $65.49 | $535,339.88 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 10 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,976 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 600 | $65.48 | $39,288.00 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,151 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 8,100 | $65.48 | $530,347.50 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,751 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,400 | $65.47 | $91,658.00 |
DisclosureSEC source: 0001179110-17-007862 · edgar.xml · nonDerivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,851 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.